Medical Segment Revenue Grows 136% Year-Over-Year
Expands CompuFlo® Physician Partnerships and Advances Medical Commercialization
Online Demonstrations More Than Double Reflecting Increased Customer Engagement
Reaffirms 2026 Outlook for Double-Digit Revenue Growth, Including Significant Growth in CompuFlo® Sales
Identifies approximately
Recent Business Highlights
- Identified cost-reduction initiatives expected to generate approximately
$400,000 in additional annual savings, strengthening the Company’s path to potential profitability in Q4 2026 and additional profitable quarters in 2027. - Expanded CompuFlo® clinical adoption across major healthcare organizations, highlighted by the initiation of clinical use at Rothman Orthopaedics, a nationally recognized orthopedic organization, and the addition of
Pain and Spine Specialists , a 22-locationNortheastern U.S. pain management network, and its medical director, Dr.Sudhir Rao , to the CompuFlo Advisor Program. - Built a pipeline of more than 500 U.S. commercial leads, supported by five dedicated medical sales professionals, approximately 15 sales consultants and three distribution partners, with federal market access through Red One Medical.
- Reinforced CompuFlo’s clinical value proposition through a peer-reviewed 79-patient
University of Texas Medical Branch study associating CompuFlo-guided epidural access with approximately 91% lower adjusted odds of composite complications compared with conventional loss-of-resistance techniques during spinal cord stimulator implantation. - Highlighted substantial market potential across an estimated 30 million-plus annual epidural procedures worldwide, including more than 11 million in the
U.S . Just 2%U.S . penetration could represent approximately$33 million in annual disposable revenue at$150 per procedure (illustrative only; not a revenue forecast). - Submitted a provisional patent application for a potential new application of CompuFlo technology in intrathecal pump refills, extending its potential beyond epidural procedures.
- Strengthened international medical commercialization through distributor engagement and market development activities in
Italy andGreece to support CompuFlo adoption and recurring sales. - Pursued global strategic partnerships through go-to-market and licensing discussions with major medical technology organizations to expand international market reach.
- Broadened dental distribution opportunities through engagement with four potential distribution channels collectively serving thousands of dental offices.
- Achieved a debt-free balance sheet by eliminating outstanding director loans through a debt-to-equity conversion, supporting the Company’s focus on financial discipline.
“During the third quarter, we continued to advance our commercial strategy while maintaining disciplined expense management,” said
“In our medical business, we are gaining traction with major healthcare organizations, highlighted by the initiation of clinical use at Rothman Orthopaedics, a nationally recognized orthopedic organization with 34 locations, and the addition of
“Looking ahead, we expect to approach profitability, or be profitable, in the fourth quarter of 2026. Our team has remained focused on identifying cost-saving opportunities across the business, with initiatives expected to generate approximately
Financial Results for the Three Months Ended
For the three months ended
Gross profit for the three months ended
Operating expenses decreased by
Net loss was
Financial Results for the Nine Months Ended
For the nine months ended
Gross profit for the nine months ended
Operating expenses decreased by
Net loss for the nine months ended
As of
2026 Outlook
Management reaffirms its full-year 2026 revenue outlook of
Management expects these initiatives, together with continued cost discipline and operating expense management, to support improved operating leverage and a meaningful reduction in cash burn compared with the prior year. The Company remains focused on increasing CompuFlo® adoption and utilization and growing recurring disposable revenue. Management expects the Company to approach or achieve profitability in the fourth quarter of 2026 and expects considerably lower losses in 2027 compared with 2026, with additional profitable quarters depending on revenue levels.
Conference Call
Milestone will host a conference call at
The conference call will be available via telephone by dialing toll free 888-506-0062 for
An audio replay of the call will be available through
About Milestone Scientific Inc.
Milestone Scientific Inc. is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2025. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
HAYDEN IR:
James Carbonara
(646)-755-7412
james@haydenir.com
Brett Maas
(646) 536-7331
brett@haydenir.com
-- Tables Follow –
MILESTONE SCIENTIFIC AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,315,401 | $ | 1,112,642 | ||||
| Accounts receivable, net of allowance for credit losses of | 1,087,584 | 680,620 | ||||||
| Accounts receivable, related party | 12,834 | 25,548 | ||||||
| Other receivable | 55,664 | - | ||||||
| Prepaid expenses and other current assets | 279,283 | 468,792 | ||||||
| Inventories | 2,735,323 | 3,781,837 | ||||||
| Advances on contracts | 1,279,102 | 1,408,395 | ||||||
| Total current assets | 6,765,191 | 7,477,834 | ||||||
| Furniture, fixtures and equipment, net | 18,795 | 19,193 | ||||||
| Intangibles, net | 27,754 | 79,063 | ||||||
| Right of use assets finance lease | 44,421 | 55,811 | ||||||
| Right of use assets operating lease | 62,433 | 150,378 | ||||||
| Other assets | 24,150 | 24,150 | ||||||
| Total assets | $ | 6,942,744 | $ | 7,806,429 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,250,262 | $ | 1,430,250 | ||||
| Accounts payable, related party | 49,810 | 1,263,651 | ||||||
| Accrued expenses and other payables | 872,925 | 995,206 | ||||||
| Accrued expenses, related party | - | 88,799 | ||||||
| Current portion of finance lease liabilities | 37,587 | 27,347 | ||||||
| Current portion of operating lease liabilities | 68,927 | 130,355 | ||||||
| Total current liabilities | 3,279,511 | 3,935,608 | ||||||
| Non-current portion of finance lease liabilities | 6,834 | 27,336 | ||||||
| Non-current portion of operating lease liabilities | - | 35,208 | ||||||
| Convertible notes payable, related parties | - | 800,000 | ||||||
| Total liabilities | $ | 3,286,345 | $ | 4,798,152 | ||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, par value | $ | 90,645 | $ | 80,487 | ||||
| Additional paid in capital | 140,524,925 | 137,418,974 | ||||||
| Accumulated deficit | (136,047,655 | ) | (133,579,668 | ) | ||||
| (911,516 | ) | (911,516 | ) | |||||
| Total stockholders’ equity | 3,656,399 | $ | 3,008,277 | |||||
| Total liabilities and stockholders’ equity | 6,942,744 | $ | 7,806,429 | |||||
MILESTONE SCIENTIFIC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||||||||||
| Three Months Ending | Three Months Ending | Nine Months Ending | Nine Months Ending | |||||||||||||
| Product sales, net | $ | 2,219,747 | $ | 2,360,117 | $ | 7,222,818 | $ | 6,916,003 | ||||||||
| Cost of products sold | 614,218 | 719,247 | 2,143,098 | 2,010,092 | ||||||||||||
| Gross profit | 1,605,529 | 1,640,870 | 5,079,720 | 4,905,911 | ||||||||||||
| Selling, general and administrative expenses | 2,321,312 | 2,739,011 | 7,474,552 | 9,026,691 | ||||||||||||
| Research and development expenses | 10,413 | 16,226 | 3,222 | 437,135 | ||||||||||||
| Depreciation and amortization expense | 20,096 | 20,104 | 59,139 | 59,040 | ||||||||||||
| Total operating expenses | 2,351,821 | 2,775,341 | 7,536,913 | 9,522,866 | ||||||||||||
| Loss from operations | (746,292 | ) | (1,134,471 | ) | (2,457,193 | ) | (4,616,955 | ) | ||||||||
| Interest (expense) income, net | (1,253 | ) | (19,488 | ) | (10,792 | ) | (14,700 | ) | ||||||||
| Loss before provision for income taxes | (747,545 | ) | (1,153,959 | ) | (2,467,985 | ) | (4,631,655 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (747,545 | ) | $ | (1,153,959 | ) | $ | (2,467,985 | ) | $ | (4,631,655 | ) | ||||
| Net loss per share applicable to common stockholders— | ||||||||||||||||
| Basic and Diluted | (0.01 | ) | (0.01 | ) | (0.03 | ) | (0.06 | ) | ||||||||
| Weighted average shares outstanding and to be issued— | ||||||||||||||||
| Basic and diluted | 93,913,021 | 82,049,984 | 90,151,697 | 81,903,323 | ||||||||||||
Source: